The present studies add to our understanding of the therapies for the early phase of SC2 by demonstrating that the inhibition of ChI3L1 with FRG and/or kasugamycin ameliorates cellular infection induced by the alpha, beta, gamma, delta, and omicron SC2 VOC. Here, CHI3L1 is linked to infection.